Member Info for valueseeker

Big fall from recent high on low volume

Big rise today on higher volume and big intra day reversal

Farn need to access funding at some stage however cashburn was reduced last spring so cash costs have probably decreased. The cash burn/ run rate you assume may not be accurate as it was based on previous coatings. Farn may wait for good news ( due on several fronts) in the months ahead before looking to raise. There are also many ways of raising funds - rights issues, partnering/ milestone payments even selling one of its pipeline drugs to a large pharma and then concentrating on the other. Who knows?

I think he said a first read out from YODA in Q 4 with a full result to follow in Q1. Thats what I read and took from the interview.

Either way clevegen still firmly on track to establish efficacy for solid tumours ( with all that could potentially mean)

and of course traumakine despite the hiccup with the steroid interference, still also POTENTIALLY a blockbuster.

The Lancet saw the potential here, with an important write up and also it got promising treatment status etc etc

Anyway , all this potential is still to be proved, and mkt cap reflects this (at 19m !).This stock also requires patience.

Should be an interesting six months ahead.

Still expecting a retest of the 55/56 support, then time to load up